Summer 2018 | Live Blog | Product Theater | Spotlight on Mild-to-Moderate Atopic Dermatitis: An Update on a Steroid-Free Topical Prescription Therapy
In the second product theater on Day 3 of the SDPA Annual Summer Conference, Dr. Pearl Kwong showcased Eucrisa for the treatment of mild to moderate atopic dermatitis. Nearly 18 million children and adults are estimated to have atopic dermatitis in the United States. Clinical manifestations of atopic dermatitis vary by anatomic location and are dependent on the age of the patient. There is ample evidence that quality of life is negatively affected for patients with atopic dermatitis mainly due to itching and lack of sleep. Topical therapy is the mainstay of treatment for patients with atopic dermatitis which includes nonpharmacologic and pharmacologic options. Nonpharmacologic options include bathing practices, moisturizers and wet wrap therapy.
Eucrisa is the first and only steroid-free topical phosphodiesterase 4 (PDE4) inhibitor for the treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. One of the benefits of Eucrisa is that it can be applied anywhere on the face and body or from “nose to toes”. The most common adverse reaction for patients who use Eucrisa is site pain, burning or tingling. The majority of these reactions improve within a week of treatment. Eucrisa contains an emollient rich vehicle which can help moisture and soften the skin. Dr. Kwong emphasized that “vehicle matters” in the approach to patients with atopic dermatitis.
In the trials on Eucrisa, it is important to note that the majority of test subjects in these trials were children revealing that the safety is well established in pediatric subjects. More than half of patients achieve significant clearance after a month of treatment with Eucrisa. Additionally, the majority of the subjects show a significant improvement in quality of life with use of Eucrisa.
Byline: Sarah Patton, MSHS, PA-C
Posted: June 30, 2018